Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Bermejo F, et al. Gastroenterol Hepatol. 2018 Mar;41(3):205-221. doi: 10.1016/j.gastrohep.2017.11.007. Epub 2018 Jan 19. Gastroenterol Hepatol. 2018. PMID: 29357999 Review. English, Spanish.
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
Guasch M, Cañete F, Ordás I, Iglesias-Flores E, Clos A, Gisbert JP, Taxonera C, Vera I, Mínguez M, Guardiola J, Rivero M, Nos P, Gomollón F, Barrio J, de Francisco R, López-Sanromán A, Martín-Arranz MD, Garcia-Planella E, Camargo R, García-López S, de Castro L, Calvet X, Esteve M, Mañosa M, Domènech E; GETECCU-ENEIDA registry. Guasch M, et al. J Gastroenterol Hepatol. 2020 Dec;35(12):2080-2087. doi: 10.1111/jgh.15084. Epub 2020 May 10. J Gastroenterol Hepatol. 2020. PMID: 32350906 Free article.
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.
Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-Sanromán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, Fe García-Sepulcre M, Monfort D, Cañete F, Domènech E; ENEIDA Study Group of GETECCU. Calafat M, et al. J Crohns Colitis. 2022 Jul 14;16(6):946-953. doi: 10.1093/ecco-jcc/jjab213. J Crohns Colitis. 2022. PMID: 34864947
Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability.
Domènech E, Zabana Y, Garcia-Planella E, López San Román A, Nos P, Ginard D, Gordillo J, Martínez-Silva F, Beltrán B, Mañosa M, Cabré E, Gassull MA. Domènech E, et al. Aliment Pharmacol Ther. 2010 Jan 15;31(2):233-9. doi: 10.1111/j.1365-2036.2009.04170.x. Epub 2009 Oct 13. Aliment Pharmacol Ther. 2010. PMID: 19832727 Free article.
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
Iborra M, Pérez-Gisbert J, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, Hinojosa E, Márquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P; Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).. Iborra M, et al. J Gastroenterol. 2017 Jul;52(7):788-799. doi: 10.1007/s00535-016-1274-1. Epub 2016 Oct 8. J Gastroenterol. 2017. PMID: 27722996
190 results